Literature DB >> 7252527

Edematous necrosis in thiamine-deficient encephalopathy of the mouse.

I Watanabe, T Tomita, K S Hung, Y Iwasaki.   

Abstract

Acute encephalopathy was produced in the adult male Swiss mouse by pyrithiamine injection in conjunction with a thiamine-deficient diet. The condition of some mice was reversed within 24 hours by a treatment of a high dose of thiamine. The lesions occurred selectively in the thalamus, pontine tegmentum, and mammillary body and were manifested by hemorrhage and edematous necrosis consisting of severe edema of astrocytes, myelin sheaths, and neuronal dendrites. Before thiamine treatment, these degenerative changes were not associated with any mesenchymal reaction. At 48 and 96 hours after thiamine treatment, these edematous changes persisted. Fat-laden macrophages appeared in the lesion. Some axons showed Wallerian-type degeneration. After three weeks of thiamine treatment, macrophages became thin and rod-shaped. Wallerian-type degeneration and myelin edema persisted. The oligodendrocytes and astrocytes were hypertrophic. These lesions of thiamine-treated encephalopathy of the mouse closely resembled the non-hemorrhagic lesions of human Wernicke encephalopathy. Mice which were concomitantly-induced with hyperglycemia and encephalopathy showed no significant differences in clinical and morphologic manifestations from the encephalopathic mice with normal blood sugar levels. Vascular permeability to horseradish peroxidase was increased only slightly at the initial stage, but was reversed in the mice which clinically responded quickly to thiamine treatment. Occasionally, persistent increase of permeability was seen in 21-day-old lesions. These findings suggested that, in thiamine-deficient encephalopathy, both nervous and vascular components in the brain were involved and that the morphologic manifestations of the nervous component were far more extensive than those of the blood vessels.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252527     DOI: 10.1097/00005072-198107000-00008

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  13 in total

Review 1.  The blood-brain barrier and selective vulnerability in experimental thiamine-deficiency encephalopathy in the mouse.

Authors:  N Harata; Y Iwasaki
Journal:  Metab Brain Dis       Date:  1996-03       Impact factor: 3.584

Review 2.  Mechanisms of neuronal cell death in Wernicke's encephalopathy.

Authors:  A S Hazell; K G Todd; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-06       Impact factor: 3.584

3.  The effect of thiamine deficiency on the structure and physiology of the rat forebrain.

Authors:  M Armstrong-James; D T Ross; F Chen; F F Ebner
Journal:  Metab Brain Dis       Date:  1988-06       Impact factor: 3.584

4.  Neuro-toxic interaction in alcohol-treated, thiamine-deficient mice.

Authors:  S C Phillips
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

5.  Vascular changes in acute Wernicke's encephalopathy.

Authors:  R Okeda; K Taki; R Ikari; N Funata
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

6.  Thalamic vacuolation in acute Wernicke's encephalopathy [corrected].

Authors:  C Byrne; G Halliday; J Ellis; C Harper
Journal:  Metab Brain Dis       Date:  1993-06       Impact factor: 3.584

Review 7.  Pathogenesis of diencephalic lesions in an experimental model of Wernicke's encephalopathy.

Authors:  P J Langlais
Journal:  Metab Brain Dis       Date:  1995-03       Impact factor: 3.584

8.  Neuropathologic changes in suckling and weanling rats with pyrithiamine-induced thiamine deficiency.

Authors:  N Horita; A Okuno; Y Izumiyama
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

9.  Blood-brain barrier dysfunction in thiamine-deficient, alcohol-treated rats.

Authors:  S C Phillips; B G Cragg
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

10.  Brain endothelial cell-cell junctions: how to "open" the blood brain barrier.

Authors:  Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.